



# Transforming **GU CANCER CARE** for Improved Patient Outcomes

**THE PHARMACIST'S ROLE IN IMPLEMENTING PRACTICE-CHANGING DATA**

The GU oncology treatment landscape is growing increasingly innovative and complex with an increasing number of therapeutic options becoming available for patient treatment, both alone as single agents, as well as in various combinations of multiple agents. While these innovations in care are improving patient outcomes, they also come with patient management complexities that require a team approach to patient management.

## SESSION OBJECTIVES

*At the end of this session, and using case-based learning scenarios, participants will be able to:*

- **REVIEW** and **EVALUATE** the impact of recent practice-changing data in genitourinary (GU) oncology, specifically in bladder cancer and renal cell carcinoma (RCC), highlighting the implications for treatment and patient care.
- **EXPLAIN** and **RECOGNIZE** actionable strategies for pharmacy professionals to enhance the cancer care experience by optimizing patient management and addressing the unique side effects and needs stemming from novel GU oncology therapies.
- **EXAMINE** multidisciplinary collaborative practice models that empower pharmacists to lead in patient care, highlighting real-world examples and best practices that can improve the patient experience and overall care delivery.

## **ON-DEMAND VIRTUAL SYMPOSIUM**

at the  
**Canadian Association of  
Pharmacy in Oncology  
Conference 2025**

Available March 27<sup>th</sup> on the  
CAPhO Conference application

## SPEAKERS



### **CHELSEA NORMORE**

**BSC(PHARM), RPH**

Clinical Pharmacist,  
Pharmacy/Medical Oncology  
Dr. H. Bliss Murphy Cancer Center  
NL Health Services  
St. John's, NL



### **MATTHEW YOUNG**

**MD, FRCPC**

Clinical Assistant Professor,  
Faculty of Medicine,  
Memorial University of  
Newfoundland,  
Medical Oncologist,  
Dr. H. Bliss Murphy Cancer Center  
NL Health Services  
St. John's, NL